StockNews.com Begins Coverage on Cumberland Pharmaceuticals (NASDAQ:CPIX)

StockNews.com assumed coverage on shares of Cumberland Pharmaceuticals (NASDAQ:CPIXGet Rating) in a research note issued to investors on Tuesday. The brokerage set a “hold” rating on the specialty pharmaceutical company’s stock.

Separately, TheStreet cut shares of Cumberland Pharmaceuticals from a “c-” rating to a “d+” rating in a research note on Tuesday, February 22nd.

Shares of CPIX stock opened at $2.55 on Tuesday. The stock has a market cap of $37.84 million, a PE ratio of -10.63 and a beta of 0.21. The company’s fifty day moving average price is $2.93 and its 200-day moving average price is $3.32. Cumberland Pharmaceuticals has a 12 month low of $2.20 and a 12 month high of $7.51. The company has a current ratio of 2.37, a quick ratio of 1.93 and a debt-to-equity ratio of 0.35.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Morgan Stanley boosted its position in shares of Cumberland Pharmaceuticals by 131.3% during the 1st quarter. Morgan Stanley now owns 11,160 shares of the specialty pharmaceutical company’s stock valued at $34,000 after acquiring an additional 6,335 shares during the last quarter. Citadel Advisors LLC bought a new stake in Cumberland Pharmaceuticals in the third quarter worth $32,000. Schonfeld Strategic Advisors LLC bought a new stake in shares of Cumberland Pharmaceuticals during the fourth quarter worth $94,000. State Street Corp bought a new stake in shares of Cumberland Pharmaceuticals during the fourth quarter worth $307,000. Finally, Marshall Wace LLP bought a new stake in shares of Cumberland Pharmaceuticals during the fourth quarter worth $373,000. Hedge funds and other institutional investors own 18.29% of the company’s stock.

Cumberland Pharmaceuticals Company Profile (Get Rating)

Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, rheumatology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of chronic and acute constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.

Recommended Stories

Receive News & Ratings for Cumberland Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cumberland Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.